Kronos Bio Inc (KRON) - Net Assets
Based on the latest financial reports, Kronos Bio Inc (KRON) has net assets worth $79.81 Million USD as of March 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($108.14 Million) and total liabilities ($28.33 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Kronos Bio Inc (KRON) asset resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $79.81 Million |
| % of Total Assets | 73.8% |
| Annual Growth Rate | N/A |
| 5-Year Change | -81.19% |
| 10-Year Change | N/A |
| Growth Volatility | 7.25 |
Kronos Bio Inc - Net Assets Trend (2018–2024)
This chart illustrates how Kronos Bio Inc's net assets have evolved over time, based on quarterly financial data. Also explore KRON total assets for the complete picture of this company's asset base.
Annual Net Assets for Kronos Bio Inc (2018–2024)
The table below shows the annual net assets of Kronos Bio Inc from 2018 to 2024. For live valuation and market cap data, see Kronos Bio Inc stock valuation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $87.58 Million | -44.95% |
| 2023-12-31 | $159.08 Million | -34.94% |
| 2022-12-31 | $244.50 Million | -29.15% |
| 2021-12-31 | $345.10 Million | -25.87% |
| 2020-12-31 | $465.52 Million | +2106.29% |
| 2019-12-31 | $-23.20 Million | -218.02% |
| 2018-12-31 | $-7.30 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Kronos Bio Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 58759500000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $60.00K | 0.07% |
| Other Comprehensive Income | $9.00K | 0.01% |
| Other Components | $682.45 Million | 779.23% |
| Total Equity | $87.58 Million | 100.00% |
Kronos Bio Inc Competitors by Market Cap
The table below lists competitors of Kronos Bio Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Top High Image
TWO:3284
|
$53.66 Million |
|
Allegiant Gold Ltd
V:AUAU
|
$53.67 Million |
|
Qliro AB
ST:QLIRO
|
$53.71 Million |
|
FIT INVEST JSC
VN:FIT
|
$53.73 Million |
|
Metair
JSE:MTA
|
$53.64 Million |
|
Hwail Pharmaceutical Co.Ltd
KQ:061250
|
$53.61 Million |
|
Instil Bio Inc.
NASDAQ:TIL
|
$53.58 Million |
|
Airmate Cayman International Co Ltd
TW:1626
|
$53.57 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Kronos Bio Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 159,078,000 to 87,580,000, a change of -71,498,000 (-44.9%).
- Net loss of 86,079,000 reduced equity.
- Share repurchases of 244,000 reduced equity.
- Other comprehensive income decreased equity by 10,000.
- Other factors increased equity by 14,835,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-86.08 Million | -98.29% |
| Share Repurchases | $244.00K | -0.28% |
| Other Comprehensive Income | $-10.00K | -0.01% |
| Other Changes | $14.84 Million | +16.94% |
| Total Change | $- | -44.95% |
Book Value vs Market Value Analysis
This analysis compares Kronos Bio Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.60x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | $-0.26 | $0.88 | x |
| 2019-12-31 | $-0.44 | $0.88 | x |
| 2020-12-31 | $8.61 | $0.88 | x |
| 2021-12-31 | $6.30 | $0.88 | x |
| 2022-12-31 | $4.35 | $0.88 | x |
| 2023-12-31 | $2.75 | $0.88 | x |
| 2024-12-31 | $1.46 | $0.88 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Kronos Bio Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -98.29%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -874.08%
- • Asset Turnover: 0.08x
- • Equity Multiplier: 1.42x
- Recent ROE (-98.29%) is below the historical average (-39.85%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | 0.00% | 0.00% | 0.00x | 0.00x | $-5.99 Million |
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-13.10 Million |
| 2020 | -13.77% | 0.00% | 0.00x | 1.10x | $-110.64 Million |
| 2021 | -43.21% | 0.00% | 0.00x | 1.13x | $-183.61 Million |
| 2022 | -52.88% | -4192.38% | 0.01x | 1.21x | $-153.74 Million |
| 2023 | -70.83% | -1791.87% | 0.03x | 1.34x | $-128.58 Million |
| 2024 | -98.29% | -874.08% | 0.08x | 1.42x | $-94.84 Million |
Industry Comparison
This section compares Kronos Bio Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $44,828,400
- Average return on equity (ROE) among peers: -124.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Kronos Bio Inc (KRON) | $79.81 Million | 0.00% | 0.35x | $53.65 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $448.19K |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $88.00 Million | -44.09% | 0.34x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $80.00K | -31.70% | 0.38x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $23.36 Million | -97.44% | 0.37x | $3.74 Billion |
About Kronos Bio Inc
Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule therapeutics to treat cancer and other serious diseases in the United States. It is developing KB-9558, a p300 KAT inhibitor development candidate which is in preclinical development for the treatment of multiple myeloma, as well as HPV-driven tumors; and KB-7898, a p300 KAT in… Read more